Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab real-world study in rheumatoid arthritis after TNF-blocker failure
ISRCTN27093749Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Medical University of Vienna. Primary endpoint: Frequency reaching low disease activity or remission by CDAI. Started Sep 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN27093749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27093749.